Private players offer new treatment

New companies, investors provide prescription for major change in medical services

Regulators in China are pushing reform in the medical sector with calls for more funding and moves to liberalize the charges at private hospitals. Meanwhile, high-end players in the industry are gearing up for investment and expansion to achieve a niche in the booming market.

Chindex International Inc, a Nasdaq-listed health company in China, is in the process of privatization. It agreed to a deal with a consortium of buyers - its own chief executive officer as well as Shanghai Fosun Pharmaceutical Co and United States-based private equity firm TPG Capital Ltd - in February.